<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03463057</url>
  </required_header>
  <id_info>
    <org_study_id>HO151</org_study_id>
    <secondary_id>2017-002605-35</secondary_id>
    <nct_id>NCT03463057</nct_id>
  </id_info>
  <brief_title>The Feasibility and Clinical Efficacy of Atezolizumab Consolidation Treatment in High Risk (IPI &gt; 2) DLBCL</brief_title>
  <acronym>HO151DLBCL</acronym>
  <official_title>A Phase II Study Evaluating the Feasibility and Clinical Efficacy of Atezolizumab Consolidation Treatment in High Risk Diffuse Large B-cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stichting Hemato-Oncologie voor Volwassenen Nederland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stichting Hemato-Oncologie voor Volwassenen Nederland</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The prognosis of Diffuse Large B cell Lymphoma (DLBCL) patients with an early relapse is&#xD;
      dismal. Atezolizumab has shown promising activity in relapsed DLBCL patients. Toxicity data&#xD;
      on atezolizumab are available for &gt; 6000 patients and is manageable. The assumption of this&#xD;
      study is that atezolizumab consolidation will result in higher disease free survival by&#xD;
      eradicating minimal residual disease In melanoma and lung cancer consolidation immunotherapy&#xD;
      after chemoradiotherapy has shown an increase in survival.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In high risk diffuse large B-cell lymphoma (DLBCL), International Prognostic Index&#xD;
      (IPI)-score ≥ 3 21% of patients will relapse within 2-years after completion of R-CHOP&#xD;
      induction treatment despite achieving a complete remission. Patient relapsing within a year&#xD;
      after R-CHOP treatment have a very poor prognosis, even after second line chemotherapy, with&#xD;
      only 15% of patients achieving a long remission. Therefore, additional therapy in first line&#xD;
      treatment is required for these patients. The immune checkpoint inhibitor atezolizumab is a&#xD;
      monoclonal antibody directed against the program death ligand 1 (PDL1). The PD1 and PDL1&#xD;
      inhibitors have shown excellent results in relapsed Hodgkin lymphoma and promising results in&#xD;
      relapsed B-cell non Hodgkin lymphoma. Given the acceptable toxicity profile of atezolizumab,&#xD;
      this study examines the efficacy and toxicity of atezolizumab as consolidation treatment&#xD;
      after R-CHOP induction in DLBCL patients at high risk of relapse.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 30, 2018</start_date>
  <completion_date type="Anticipated">April 2025</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease free survival (DFS) measured from the date of registration to relapse or death from any cause whichever comes first.</measure>
    <time_frame>2 year after inclusion last patient</time_frame>
    <description>To evaluate the 2-year DFS for patients in complete metabolic remission after R-CHOP induction</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>(Severe) Adverse Events and the relation of adverse events in time to the recovery of the T-cell repertoire.</measure>
    <time_frame>2 years after inclusion last patient</time_frame>
    <description>To evaluate toxicity and assess the relation of adverse events in time to recovery of the T-cell repertoire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS), calculated from registration until death from any cause. Patients still alive or lost to follow up are censored at the last date known to be alive.</measure>
    <time_frame>2 years after inclusion last patient</time_frame>
    <description>To evaluate the 2-year OS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The relationship between MRD status at the end-of-induction and end-of-consolidation therapy.</measure>
    <time_frame>2 years after inclusion last patient</time_frame>
    <description>To evaluate MRD status at the end of induction therapy, at various time points during consolidation treatment and at the end of consolidation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The relation between MRD conversion and 2-years DFS and OS.</measure>
    <time_frame>2 years after inclusion last patient</time_frame>
    <description>To evaluate if there is a relation between MRD conversion and 2-years DFS and OS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The relation between the T-cell and NK cell repertoire and adverse events.</measure>
    <time_frame>2 years after inclusion last patient</time_frame>
    <description>To evaluate the recovery of the T-cell and NK cell repertoire after induction therapy and at various time points during consolidation treatment in relation to toxicity and efficacy.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Atezolizumab spinal fluid concentration as assessed by spinal fluid measurements will be performed in patients receiving atezolizumab.</measure>
    <time_frame>2 years after inclusion last patient</time_frame>
    <description>To assess the crossing of the blood-brain barrier of atezolizumab by measuring atezolizumab concentrations in het cerebrospinal fluid.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">114</enrollment>
  <condition>NHL</condition>
  <condition>DLBCL</condition>
  <arm_group>
    <arm_group_label>Atezolizumab</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>18 cycles atezolizumab followed by 12 months of observation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atezolizumab</intervention_name>
    <description>Intervention Atezolizumab starts after 6 - 8 R-CHOP induction cycles (Rituximab, Cyclophosphamide, Hydroxo-doxorubicin, Vincristine and Prednisone (R-CHOP)); 18 cycles Atezolizumab followed by 12 months of observation</description>
    <arm_group_label>Atezolizumab</arm_group_label>
    <other_name>Tecentriq</other_name>
    <other_name>L01XC</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18-75 (inclusive) years&#xD;
&#xD;
          -  Patients with a confirmed histologic diagnosis of diffuse large B-cell lymphoma&#xD;
             (DLBCL-NOS) based upon a representative histology specimen according to the World&#xD;
             Health Association (WHO) classification, revision 2016&#xD;
&#xD;
          -  Ann Arbor stages II-IV&#xD;
&#xD;
          -  WHO performance status 0 - 1&#xD;
&#xD;
          -  International Prognostic Index (IPI) ≥ 3 at diagnosis&#xD;
&#xD;
          -  Complete metabolic remission (Deauville 1-3) after 6-8 cycles of R-CHOP according to&#xD;
             the Lugano criteria&#xD;
&#xD;
        Of note:&#xD;
&#xD;
          1. Rituximab may have been administered either intravenously or subcutaneously. A&#xD;
             rituximab biosimilar may have been used when it is approved for the indication of&#xD;
             DLBCL.&#xD;
&#xD;
          2. Patients should have received at least 6 cycles R-CHOP. Dose reductions for&#xD;
             vincristine are allowed during R-CHOP. Dose reductions because of bone marrow toxicity&#xD;
             are allowed but cannot exceed &gt;15% of cumulative dose of doxorubicin and&#xD;
             cyclophosphamide.&#xD;
&#xD;
          3. Central nervous system prophylaxis (MTX) by intrathecal therapy or IV is allowed.&#xD;
&#xD;
          4. Fludeoxyglucose Positron Emission Tomography (18F-FDG-PET) scan should have been made&#xD;
             4-8 weeks after last induction cycle&#xD;
&#xD;
          5. Histologically confirmed false positive EoT PET-scans are eligible.&#xD;
&#xD;
               -  Negative pregnancy test at study entry&#xD;
&#xD;
               -  Patient is willing and able use adequate contraception during and until 5 months&#xD;
                  after the last protocol treatment.&#xD;
&#xD;
               -  Patient is capable of giving a written informed consent&#xD;
&#xD;
             Exclusion Criteria:&#xD;
&#xD;
             Diagnosis&#xD;
&#xD;
             • All histopathological diagnoses other than DLBCL-NOS according to the WHO&#xD;
             classification, revision 2016, including:&#xD;
&#xD;
             - High-grade B-cell lymphoma with a double/triple translocation with MYC, BCL2 and/or&#xD;
             BCL6. Please note that patients with an isolated MYC translocation or an isolated BCL2&#xD;
             translocation or an isolated BCL-6 translocation are eligible (single hit&#xD;
             translocation).&#xD;
&#xD;
               -  Testicular large B-cell lymphoma&#xD;
&#xD;
               -  Primary mediastinal B cell lymphoma&#xD;
&#xD;
               -  Transformed indolent lymphoma&#xD;
&#xD;
               -  Post-transplant lymphoproliferative disorder&#xD;
&#xD;
             Organ dysfunction&#xD;
&#xD;
               -  Clinical signs of severe pulmonary dysfunction&#xD;
&#xD;
               -  Clinical signs of heart failure (New York Heart Association (NYHA) classification&#xD;
                  II-IV)&#xD;
&#xD;
               -  Symptomatic coronary artery disease or cardiac arrhythmias not well controlled&#xD;
                  with medication.&#xD;
&#xD;
               -  Myocardial infarction during the last 6 months&#xD;
&#xD;
               -  Significant renal dysfunction (serum creatinine ≥ 150 umol/l or clearance ≤&#xD;
                  30ml/min&#xD;
&#xD;
             Creatinine clearance (CrCl) may be calculated by Cockcroft -Gault formula:&#xD;
&#xD;
             CrCl = (140 - age [in years]) x weight [kg] (x 0.85 for females)/(0.815 x serum&#xD;
             creatinine [μmol/L])&#xD;
&#xD;
             • Inadequate hematological function: hemoglobin &lt; 5.5 mmol/L Absolute Neutrophil Count&#xD;
             (ANC) &lt; 1.0x10↑9/L or platelets &lt; 75x10↑9 /L&#xD;
&#xD;
               -  Signs or known history of bleeding disorder.&#xD;
&#xD;
               -  Significant hepatic dysfunction (total bilirubin ≥ 1.5x upper limit of normal&#xD;
                  (ULN) or transaminases ≥ 2.5 x ULN), unless related to Gilberts syndrome.&#xD;
&#xD;
               -  Clinical signs of severe cerebral dysfunction&#xD;
&#xD;
               -  Patients with a history of uncontrolled seizures, central nervous system&#xD;
                  disorders or psychiatric disability judged by the investigator to be clinically&#xD;
                  significant and adversely affecting compliance to study drugs&#xD;
&#xD;
               -  Major surgery within the last 4 weeks&#xD;
&#xD;
             Known or suspected infection • Known active bacterial, viral, fungal, mycobacterial,&#xD;
             parasitic, or other infection or any major episode of infection requiring treatment&#xD;
             with IV antibiotics or hospitalization within 4 weeks of the start of Cycle 1.&#xD;
             Suspected active or latent tuberculosis needs to be confirmed by positive interferon&#xD;
             gamma (IFN-γ) release assay&#xD;
&#xD;
             • Patients known to be Human Immuno-deficiency Virus (HIV)-positive&#xD;
&#xD;
               -  Active chronic hepatitis B or C infection&#xD;
&#xD;
               -  Administration of a live, attenuated vaccine within 4 weeks before date of&#xD;
                  registration or anticipation that such a live attenuated vaccine will be required&#xD;
                  during the study and for a period of 5 months after discontinuation of&#xD;
                  atezolizumab&#xD;
&#xD;
             Auto-immune • Any active or history of documented autoimmune disease, including but&#xD;
             not limited to myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus&#xD;
             erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis&#xD;
             associated with antiphospholipid syndrome, Wegener's granulomatosis, Sjögren's&#xD;
             syndrome, Guillain-Barré syndrome, multiple sclerosis, vasculitis, or&#xD;
             glomerulonephritis.&#xD;
&#xD;
             The following exceptions are allowed: Patients with autoimmune-related hypothyroidism&#xD;
             or type 1 diabetes mellitus who are on stable treatment.&#xD;
&#xD;
               -  History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g.,&#xD;
                  bronchiolitis obliterans), drug-induced pneumonitis, idiopathic pneumonitis, or&#xD;
                  evidence of active pneumonitis per chest computer tomography (CT) scan at&#xD;
                  screening.&#xD;
&#xD;
               -  Patients with uncontrolled asthma or allergy, requiring systemic steroid&#xD;
                  treatment&#xD;
&#xD;
               -  Regular treatment with corticosteroids within the 4 weeks prior to date of&#xD;
                  registration, unless administered for indications other than NHL at a dose&#xD;
                  equivalent to &lt; 30 mg/day prednisone/prednisolone&#xD;
&#xD;
             General&#xD;
&#xD;
             • Serious underlying medical conditions, which could impair the ability of the patient&#xD;
             to participate in the trial (e.g. ongoing infection, uncontrolled diabetes mellitus,&#xD;
             gastric ulcers, active autoimmune disease)&#xD;
&#xD;
             • Current participation in another clinical trial interfering with this trial&#xD;
&#xD;
             • History of active cancer during the past 5 years, except basal cell carcinoma of the&#xD;
             skin, stage 0 cervical carcinoma or carcinoma in situ (for which no systemic treatment&#xD;
             was indicated)&#xD;
&#xD;
             • Life expectancy &lt; 6 months&#xD;
&#xD;
             • Any psychological, familial, sociological and geographical condition potentially&#xD;
             hampering compliance with the study protocol and follow-up schedule&#xD;
&#xD;
             Prior treatment&#xD;
&#xD;
               -  Prior treatment with Atezolizumab, or anti-programmed cell death protein-1 (anti&#xD;
                  PD-1) or PDL-1 antibodies.&#xD;
&#xD;
               -  Prior treatment with CD137 agonists or immune checkpoint blockade therapies,&#xD;
                  including anti-CTLA4 therapeutic antibodies.&#xD;
&#xD;
               -  Treatment with systemic immunostimulatory agents (including but not limited to&#xD;
                  IFN, interleukin [IL]-2) within 6 weeks or 5 half-lives of the drug, whichever is&#xD;
                  shorter, prior to Cycle 1, Day 1.&#xD;
&#xD;
               -  Treatment with systemic immunosuppressive medications, including but not limited&#xD;
                  to prednisone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and&#xD;
                  anti-tumor necrosis factor (anti-TNF) agents within 2 weeks prior to date of&#xD;
                  registration; inhaled corticosteroids and mineralocorticoids are allowed.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>M. Nijland, PhD/MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NL-Groningen-UMCG</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Heleen Visser-Wisselaar, PhD</last_name>
    <phone>+31 (0)10 704 1560</phone>
    <email>hdc@erasmusmc.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Helma Zanders</last_name>
    <phone>+31 (0)10 704 1560</phone>
    <email>hdc@erasmusmc.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>BE-Antwerpen Edegem-UZA</name>
      <address>
        <city>Antwerpen</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>BE-Antwerpen-ZNASTUIVENBERG</name>
      <address>
        <city>Antwerpen</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>BE-Brugge-AZBRUGGE</name>
      <address>
        <city>Brugge</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>BE-Leuven-UZLEUVEN</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>BE-Roeselare-AZDELTA</name>
      <address>
        <city>Roeselare</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>NL-Amersfoort-MEANDERMC</name>
      <address>
        <city>Amersfoort</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>NL-Amsterdam-OLVG</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>NL-Amsterdam-VUMC</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>NL-Apeldoorn-GELREAPELDOORN</name>
      <address>
        <city>Apeldoorn</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>NL-Breda-AMPHIA</name>
      <address>
        <city>Breda</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>NL-Delft-RDGG</name>
      <address>
        <city>Delft</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>NL-Den Bosch-JBZ</name>
      <address>
        <city>Den Bosch</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>NL-Den Haag-HAGA</name>
      <address>
        <city>Den Haag</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>NL-Dordrecht-ASZ</name>
      <address>
        <city>Dordrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>NL-Ede-ZGV</name>
      <address>
        <city>Ede</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>NL-Eindhoven-CATHARINA</name>
      <address>
        <city>Eindhoven</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>NL-Eindhoven-MAXIMAMC</name>
      <address>
        <city>Eindhoven</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>NL-Enschede-MST</name>
      <address>
        <city>Enschede</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>NL-Groningen-UMCG</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>NL-Groningen-UMCG</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>G. Huls</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NL-Hilversum-TERGOOI</name>
      <address>
        <city>Hilversum</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>NL-Hoofddorp-SPAARNEGASTHUIS</name>
      <address>
        <city>Hoofddorp</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>NL-Leeuwarden-MCL</name>
      <address>
        <city>Leeuwarden</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>NL-Leiden-LUMC</name>
      <address>
        <city>Leiden</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>NL-Maastricht-MUMC</name>
      <address>
        <city>Maastricht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>NL-Nieuwegein-ANTONIUS</name>
      <address>
        <city>Nieuwegein</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>NL-Nijmegen-CWZ</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>NL-Rotterdam-ERASMUSMC</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>NL-Rotterdam-MAASSTADZIEKENHUIS</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>NL-Sittard-Geleen-ZUYDERLAND</name>
      <address>
        <city>Sittard</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>NL-Tilburg-ETZ</name>
      <address>
        <city>Tilburg</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>NL-Utrecht-UMCUTRECHT</name>
      <address>
        <city>Utrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>NL-Zwolle-ISALA</name>
      <address>
        <city>Zwolle</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Netherlands</country>
  </location_countries>
  <link>
    <url>http://www.hovon.nl</url>
    <description>HOVON website</description>
  </link>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>February 23, 2018</study_first_submitted>
  <study_first_submitted_qc>March 6, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 13, 2018</study_first_posted>
  <last_update_submitted>March 22, 2021</last_update_submitted>
  <last_update_submitted_qc>March 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atezolizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

